Your browser doesn't support javascript.
loading
Effect of zoledronic acid and pamidronate on renal function.
Koss, Katherine; Kocek, Melissa; King, Tiffany; Hornung, Monika.
Afiliación
  • Koss K; Department of Pharmacy, Rush University Medical Center; Chicago, IL, USA.
  • Kocek M; Department of Pharmacy, Rush University Medical Center; Chicago, IL, USA.
  • King T; Department of Pharmacy, Rush University Medical Center; Chicago, IL, USA.
  • Hornung M; Department of Pharmacy, Rush University Medical Center; Chicago, IL, USA.
J Oncol Pharm Pract ; : 10781552241284635, 2024 Sep 17.
Article en En | MEDLINE | ID: mdl-39285742
ABSTRACT

BACKGROUND:

There is limited data on the effect bisphosphonates have on renal function and the use of bisphosphonates in patients with baseline renal dysfunction.

OBJECTIVE:

The purpose of this study was to determine the incidence of acute kidney injury (AKI) in patients after receiving zoledronic acid or pamidronate.

METHODS:

A retrospective cohort analysis was conducted of patients who received one dose of a bisphosphonate, either zoledronic acid or pamidronate. The primary objective of this study was to determine the incidence of AKI after bisphosphonate administration. Baseline characteristics were compared, and unadjusted analyses of primary and secondary outcomes were completed using Pearson's chi-square or Fisher's exact test for categorical data and Mann-Whitney U test for continuous data.

RESULTS:

There was no difference found in AKI incidence between zoledronic acid and pamidronate (17.1% vs. 15.0%; p = 1.00). Additionally, there was no difference found in AKI incidence between patients with baseline renal dysfunction and those without, (25.0% vs. 15.0%; p = 0.322). There were no differences observed in either corrected calcium within seven days or serum creatinine (SCr) within 30 days returning to baseline after administration, nor were there differences in fever or hypophosphatemia incidences.

CONCLUSION:

Bisphosphonates may be used to treat hypercalcemia of malignancy in patients with and without renal dysfunction. AKI may occur post infusion; however, long-term effects on renal function are infrequent when hydrating patients prior to administration and adhering to the manufacturer's recommended infusion rate.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido